Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash

TEVA PHARMACEUTICAL INDUSTRIES LTD

Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).
Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).
Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.
Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.
2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.

Period: quarter ended March 31, 2026
Revenue: Revenues of $4.0 billion
EPS: GAAP diluted EPS of $0.31
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001171843-26-002796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.